VF
IMUC

Virtu Financial’s ImmunoCellular Therapeutics, Ltd. IMUC Stock Holding History

Virtu Financial’s Portfolio IMUC Stock Details IMUC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-71,027
Closed -$15K – 2264
2018
Q3 		$15K Sell
71,027
-53,168
-43% -$12.3K ﹤0.01% 1428
2018
Q2 		$32K Sell
124,195
-107,541
-46% -$27.9K ﹤0.01% 1823
2018
Q1 		$58K Buy
231,736
+38,243
+20% +$10.6K ﹤0.01% 1687
2017
Q4 		$61K Buy
193,493
+162,106
+516% +$55.2K ﹤0.01% 2044
2017
Q3 		$12K Buy
+31,387
New +$15.3K ﹤0.01% 2404

Other funds holding IMUC

WS
Wedbush Securities Los Angeles, California $3.88B AUM 32.38% 1-Year Est. Return

Virtu Financial's IMUC Position: Q4 2018 in Review

Virtu Financial sold out of ImmunoCellular Therapeutics, Ltd. (IMUC) in Q4 2018, closing a stake of 71,027 shares — an estimated $15K sold.

Virtu Financial first reported a position in IMUC in Q3 2017 and held it in 5 quarters. The position peaked at $61K in Q4 2017. 3 funds tracked by Wall St. Rank hold IMUC as of Q4 2018.

  • Virtu Financial reported no remaining ImmunoCellular Therapeutics, Ltd. position as of Q4 2018 after selling out during the quarter.
  • Virtu Financial sold 71,027 ImmunoCellular Therapeutics, Ltd. shares in Q4 2018, an estimated $15K.
  • Virtu Financial first reported a position in ImmunoCellular Therapeutics, Ltd. in Q3 2017 and held it in 5 quarters.
  • Virtu Financial's ImmunoCellular Therapeutics, Ltd. position peaked at $61K in Q4 2017.
  • 3 funds tracked by Wall St. Rank held ImmunoCellular Therapeutics, Ltd. as of Q4 2018.

Based on Virtu Financial's 13F filing for Q4 2018, filed 16 Jan 2019.